Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Chemotherapy Induced Pain clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07919457
Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study
The goal of this clinical trial is to find out whether a phenotype-based pain management approach can reduce chronic pain in adults (18 years and older) who have completed curative treatment for head and neck cancer and continue to experience chronic post-treatment pain. The main questions it aims to answer are: * Does a phenotype-based pain management approach reduce participants' average pain by at least 75% after one month of treatment? * Is the treatment safe, with 10% or fewer participants stopping treatment because of side effects? Participants will: * Attend three study visits over one month (at baseline, 2 weeks, and 4 weeks). * Complete questionnaires about their pain, anxiety, depression, medication side effects, and use of pain medicines. * Undergo a detailed examination to identify the type (phenotype) of their pain. * Receive a treatment plan tailored to their pain phenotype, which may include medications, trigger point injections, or nerve blocks, depending on their symptoms and pain severity. * Return for follow-up visits to assess pain relief, medication side effects, and use of breakthrough pain medication.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-05
1 state
NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
Gender: All
Ages: 18 Years - Any
Updated: 2026-09-16
14 states